Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $280.76M |
| Gross Profit (TTM) | $60.56M |
| EBITDA | $8.78M |
| Operating Margin | -4.29% |
| Return on Equity | -7.55% |
| Return on Assets | -2.47% |
| Revenue/Share (TTM) | $3.26 |
| Book Value | $3.09 |
| Price-to-Book | 1.70 |
| Price-to-Sales (TTM) | 1.77 |
| EV/Revenue | 1.536 |
| EV/EBITDA | 131.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 50.30% |
| Shares Outstanding | $89.32M |
| Float | $58.46M |
| % Insiders | 14.28% |
| % Institutions | 73.20% |
Volatility is currently expanding
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the UBS Global Healthcare Conference on Tuesday, November 10th, 2026 at 12:30 pm ET. A webcast of the event will be available at the link here.
Strata Critical Medical NASDAQ: SRTA reported fiscal third-quarter 2026 revenue growth of 50.3% from a year earlier, alongside higher adjusted EBITDA, improved logistics margins and record free cash flow, as the company expanded its integrated transplant-services platform.
Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 Q3 2026 net loss from continuing operations of $(7.6) million or (10.3)% of revenue Adjusted EBITDA (1) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0% Cash flow from operating activities was $9.5 million in Q3 2026; Free Cash Flow (1) was $8.6 million in Q3 2026 Announced $20 million share repurchase authorization; will be deployed along with continued M&A strategy execution NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the third quarter ended September 30, 2026 on Tuesday, November 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company's website at https://ir.stratacritical.com/.
Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SRTA and any ticker you trade — then tracks every position and per-strategy win rate.
